Table of contents
Volume 86, Issue 8
Published online 22 April 2002 (1205-1366)
Editorial |
Clinical |
Molecular and Cellular Pathology |
Genetics and Genomics |
Experimental Therapeutics |
Letters to the Editor
Obituary
Top of pageEditorial
Getting the right dose in cancer chemotherapy – time to stop using surface area? FREE
D R Newell
Br J Cancer 86: 1207-1208; doi:10.1038/sj.bjc.6600226
Clinical
Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort FREE
C Foster, D G R Evans, R Eeles, D Eccles, S Ashley, L Brooks, R Davidson, J Mackay, P J Morrison and M Watson
Br J Cancer 86: 1209-1216; doi:10.1038/sj.bjc.6600253
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer FREE
F G Ebeling, P Stieber, M Untch, D Nagel, G E Konecny, U M Schmitt, A Fateh-Moghadam and D Seidel
Br J Cancer 86: 1217-1222; doi:10.1038/sj.bjc.6600248
The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction FREE
J Wayman, M K Bennett, S A Raimes and S M Griffin
Br J Cancer 86: 1223-1229; doi:10.1038/sj.bjc.6600252
A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma FREE
A Baars, A M E Claessen, J Wagstaff, G Giaccone, R J Scheper, S Meijer, M J A G Schakel, H E Gall, C J L M Meijer, J B Vermorken, H M Pinedo and A J M van den Eertwegh
Br J Cancer 86: 1230-1234; doi:10.1038/sj.bjc.6600254
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? FREE
S Shah, J Hardy, E Rees, J Ling, B Gwilliam, C Davis, K Broadley and R A'Hern
Br J Cancer 86: 1235-1237; doi:10.1038/sj.bjc.6600249
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site FREE
A G Macdonald, M C Nicolson, L M Samuel, A W Hutcheon and F Y Ahmed
Br J Cancer 86: 1238-1242; doi:10.1038/sj.bjc.6600258
The level of haemoglobin in anaemic cancer patients correlates positively with quality of life FREE
M Lind, C Vernon, D Cruickshank, P Wilkinson, T Littlewood, N Stuart, C Jenkinson, P Grey-Amante, H Doll and D Wild
Br J Cancer 86: 1243-1249; doi:10.1038/sj.bjc.6600247
Molecular and Cellular Pathology
CXCR4/CXCL12 expression and signalling in kidney cancer FREE
A J Schrader, O Lechner, M Templin, K E J Dittmar, S Machtens, M Mengel, M Probst-Kepper, A Franzke, T Wollensak, P Gatzlaff, J Atzpodien, J Buer and J Lauber
Br J Cancer 86: 1250-1256; doi:10.1038/sj.bjc.6600221
Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients FREE
T Kubota, H Fujiwara, Y Ueda, T Itoh, T Yamashita, T Yoshimura, K Okugawa, Y Yamamoto, Y Yano and H Yamagishi
Br J Cancer 86: 1257-1261; doi:10.1038/sj.bjc.6600233
Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy FREE
D W Lambert, I S Wood, A Ellis and S P Shirazi-Beechey
Br J Cancer 86: 1262-1269; doi:10.1038/sj.bjc.6600264
Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma FREE
J Rohloff, J Zinke, K Schoppmeyer, A Tannapfel, H Witzigmann, J Mössner, C Wittekind and K Caca
Br J Cancer 86: 1270-1275; doi:10.1038/sj.bjc.6600232
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer FREE
K J Turner, J P Crew, C C Wykoff, P H Watson, R Poulsom, J Pastorek, P J Ratcliffe, D Cranston and A L Harris
Br J Cancer 86: 1276-1282; doi:10.1038/sj.bjc.6600215
Genetics and Genomics
Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns FREE
V Dangles, V Lazar, P Validire, S Richon, M Wertheimer, V Laville, J-L Janneau, M Barrois, C Bovin, T Poynard, G Vallancien and D Bellet
Br J Cancer 86: 1283-1289; doi:10.1038/sj.bjc.6600239
Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators FREE
T Schlott, J G Scharf, C Gorzel, P Middel and H Spring
Br J Cancer 86: 1290-1296; doi:10.1038/sj.bjc.6600238
Experimental Therapeutics
How to calculate the dose of chemotherapy FREE
H Gurney
Br J Cancer 86: 1297-1302; doi:10.1038/sj.bjc.6600139
Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-
FREE
K Nishida, T Furumatsu, I Takada, A Kawai, A Yoshida, T Kunisada and H Inoue
Br J Cancer 86: 1303-1309; doi:10.1038/sj.bjc.6600241
Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion FREE
A Siegert, C Rosenberg, W D Schmitt, C Denkert and S Hauptmann
Br J Cancer 86: 1310-1315; doi:10.1038/sj.bjc.6600224
Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs FREE
S Calatayud, T D Warner and J A Mitchell
Br J Cancer 86: 1316-1321; doi:10.1038/sj.bjc.6600240
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215 FREE
Z Szereday, A V Schally, A Nagy, A Plonowski, A M Bajo, G Halmos, K Szepeshazi and K Groot
Br J Cancer 86: 1322-1327; doi:10.1038/sj.bjc.6600235
Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length FREE
X-X Tian, J C-S Pang, J Zheng, J Chen, S S T To and H-K Ng
Br J Cancer 86: 1328-1332; doi:10.1038/sj.bjc.6600244
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease FREE
D Re, C Wickenhauser, T Ahmadi, E Buchdunger, M Kochanek, V Diehl and J Wolf
Br J Cancer 86: 1333-1335; doi:10.1038/sj.bjc.6600243
Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes FREE
P Savage, P Cowburn, A Clayton, S Man, A McMichael, N Lemoine, A Epenetos and G Ogg
Br J Cancer 86: 1336-1342; doi:10.1038/sj.bjc.6600223
Aminolaevulinic acid-induced photodynamic therapy: cellular responses to glucose starvation FREE
L Wyld, M Tomlinson, M W R Reed and N J Brown
Br J Cancer 86: 1343-1347; doi:10.1038/sj.bjc.6600234
In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles FREE
T D Bradshaw, M-S Chua, H L Browne, V Trapani, E A Sausville and M F G Stevens
Br J Cancer 86: 1348-1354; doi:10.1038/sj.bjc.6600225
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: Role of oxygenation status and tumour size FREE
M Weinmann, O Thews, T Schroeder and P Vaupel
Br J Cancer 86: 1355-1361; doi:10.1038/sj.bjc.6600237
Letters to the Editor
-Heregulin has no biological significance in primary breast cancer FREE
E A Sánchez-Valdivieso, J J Cruz, R Salazar, M del Mar Abad, A Gómez-Alonso, A Gómez and R González-Sarmiento
Br J Cancer 86: 1362-1363; doi:10.1038/sj.bjc.6600245
Early life exposure to oestrogen and testicular cancer risk: evidence against an aetiological hypothesis FREE
C C Hsieh, M Lambe, D Trichopoulos, A Ekbom, O Akre and H-O Adami
Br J Cancer 86: 1363-1364; doi:10.1038/sj.bjc.6600246
Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil FREE
C M Ulrich and J D Potter
Br J Cancer 86: 1365; doi:10.1038/sj.bjc.6600229
Reply: Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil FREE
B Iacopetta and H Elsaleh
Br J Cancer 86: 1366; doi:10.1038/sj.bjc.6600230
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
